• Users Online: 4071
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2022  |  Volume : 11  |  Issue : 2  |  Page : 204-211

Dose kelofan syrup effective for clinical symptoms and biochemical factorsin COVID-19 patients? A double-blind clinical trials


1 Traditional Medicine and Hydrotherapy Research Center, Ardabil University Of Medical Sciences, Ardabil, Iran
2 Department of Infectious Disease and Tropical Medicine, Ardabil University of Medical Science, Ardabil, Iran
3 Traditional Medicine and Hydrotherapy Research Center, Ardabil University Of Medical Sciences, Ardabil, Iran; School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
4 Department of Infectious Disease and Tropical Medicine, Imam Khomeini Hospital, Ardabil University of Medical Sciences, Ardabil, Iran
5 Traditional Medicine and Hydrotherapy Research Center, Ardabil University Of Medical Sciences, Ardabil, Iran; Pharmaceutical Sciences Research Center, Ardabil University of Medical Sciences, Ardabil, Iran

Correspondence Address:
Dr. Ramin Nasimi Doost Azgomi
Traditional Medicine and Hydrotherapy Research Center, Ardabil University, Of Medical Sciences, Ardabil, Iran; Pharmaceutical Sciences Research Center, Ardabil University of Medical Sciences, Ardabil
Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jrptps.JRPTPS_3_22

Rights and Permissions

Introduction: COVID-19 is one of the most severe, intestinal, respiratory, and systemic infections in animals and humans. The purpose of this experiment was to evaluate the effect of kelofan syrup on biochemical factors and clinical signs of patients with COVID-19. Materials and Methods: This randomized clinical trial was performed on 60 hospitalized patients with moderate or severe COVID-19. The intervention group received 7.5 cc of kelofan syrup(a traditional Persian medicine product) every 12 hours for one week and the placebo group received 7.5 cc of placebo syrup. Serum levels of white blood cells (WBCs), C - reactive protein (CRP), lactate dehydrogenase (LDH), creatinine, lymphocyte, and clinical outcomes were measured before the beginning of the intervention and on day 7. Results: Kelofan syrup enhanced the white blood cell and reduced creatinine and LDH in the syrup group. However, serum levels of WBC, lymphocyte, CRP, LDH, and creatinine(P > 0.05) in the kelofan group at the end of the study did not significantly change than in the placebo group. Also, clinical outcomes such as fever, respiratory rate, saturated oxygen, cough, dyspnea, myalgia, duration of hospitalization, and fatigue did not change significantly from in the placebo group. Conclusion: our findings indicate that kelofan syrup for seven days could not alter biochemical and clinical outcomes than in the placebo group in patients with COVID-19. However, in some clinical symptoms such as cough, dyspnea, weakness, and biochemical factors like WBC, Cr, and LDH, a significant change was observed at the end of hospitalization in the intervention group.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed144    
    Printed8    
    Emailed0    
    PDF Downloaded29    
    Comments [Add]    

Recommend this journal